eamdacademy.org-3onf-1794452424-g935757564 1794452424 Eurasian Academy of Medicine and Dentistry info@eamdacademy.org Eurasian Academy of Medicine and Dentistry Journal of Applied Pharmaceutical Technologies and Systems J Appl Pharm Technol Syst 3149-9589 2026 5 1 Victor Santos Rafael Costa Bruno Teixeira 2026 10.68159/g935757564 https://eamdacademy.org/pub/journal/3/article/g935757564 Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST, et al. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev. 2017;108:25-38. Agrahari V, Agrahari V. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. Drug Discov Today. 2018;23(5):974-91. Faria M, Björnmalm M, Thurecht KJ, Kent SJ, Parton RG, Kavallaris M, et al. Minimum information reporting in bio–nano experimental literature. Nat Nanotechnol. 2018;13(9):777-85. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: An update. Bioeng Transl Med. 2019;4(3):e10143. Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084-7. He H, Liu L, Morin EE, Liu M, Schwendeman A. Survey of clinical translation of cancer nanomedicines—lessons learned from successes and failures. Acc Chem Res. 2019;52(9):2445-61. Guidolin K, Zheng G. Nanomedicines lost in translation. ACS Nano. 2019;13(12):13620-6. Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19(5):566-75. Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20(1):710-24. Germain M, Caputo F, Metcalfe S, Tosi G, Spring K, Åslund AK, et al. Delivering the power of nanomedicine to patients today. J Control Release. 2020;326:164-71. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101-24. Younis MA, Tawfeek HM, Abdellatif AA, Abdel-Aleem JA, Harashima H. Clinical translation of nanomedicines: Challenges, opportunities, and keys. Adv Drug Deliv Rev. 2022;181:114083. Kulkarni JA, Witzigmann D, Chen S, Cullis PR, Van Der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc Chem Res. 2019;52(9):2435-44. Shi Y, Van der Meel R, Chen X, Lammers T. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics. 2020;10(17):7921. Đorđević S, Gonzalez MM, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500-25. Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B. 2022;12(7):3028-48. Wang G, Wang N, Xia X, Ismail M, Shi B. Clinical translation of nanomedicines for brain diseases: Current challenges and future directions. J Control Release. 2025;114426. Joyce P, Allen CJ, Alonso MJ, Ashford M, Bradbury MS, Germain M, et al. A translational framework to DELIVER nanomedicines to the clinic. Nat Nanotechnol. 2024;19(11):1597-611. Zhang P, Xiao Y, Sun X, Lin X, Koo S, Yaremenko AV, et al. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects. Med. 2023;4(3):147-67. Tong F, Wang Y, Gao H. Progress and challenges in the translation of cancer nanomedicines. Curr Opin Biotechnol. 2024;85:103045. Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019;25:85-98. Couvreur P. Nanomedicine: From where are we coming and where are we going? J Control Release. 2019;311:319-21. Ikeda-Imafuku M, Wang LL, Rodrigues D, Shaha S, Zhao Z, Mitragotri S. Strategies to improve the EPR effect: a mechanistic perspective and clinical translation. J Control Release. 2022;345:512-36. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-94. Souri M, Soltani M, Kashkooli FM, Shahvandi MK, Chiani M, Shariati FS, et al. Towards principled design of cancer nanomedicine to accelerate clinical translation. Mater Today Bio. 2022;13:100208. Hua S, De Matos MB, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. Front Pharmacol. 2018;9:790. Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:360. Lammers T, Ferrari M. The success of nanomedicine. Nano Today. 2020;31:100853. Metselaar JM, Lammers T. Challenges in nanomedicine clinical translation. Drug Deliv Transl Res. 2020;10(3):721-5. Wu J. The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med. 2021;11(8):771. Pallares RM, Barmin RA, Wang A, Kiessling F, Lammers T. Clinical cancer nanomedicines. J Control Release. 2025;385:113991. Hoang Thi TT, Pilkington EH, Nguyen DH, Lee JS, Park KD, Truong NP. The importance of poly (ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation. Polymers (Basel). 2020;12(2):298. Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154:163-75.